CD8A and neoplasm: This new approach of IL-10-directed cancer therapy demonstrated low toxicity while exhibiting potent antitumor activity, primarily by reinvigorating and expanding terminally exhausted CD8+ tumor-infiltrating lymphocytes (TILs) [65].